Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

1.9K
The present protocol describes obtaining the pressure-volume relationship through transesophageal pacing, which serves as a valuable tool in evaluating diastolic function in mouse models of heart...
1.9K
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

6.2K
This protocol integrated near-infrared spectroscopy into conventional cardiopulmonary exercise testing to identify the involvement of the cerebral hemodynamic response in exercise intolerance in patients with heart...
6.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

768
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

720
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

13.9K
Here, we present a protocol to produce tachycardia-induced cardiomyopathy in swine. This model represents a potent way to study the hemodynamics of progressive chronic heart failure and the effects of applied...
13.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference.

Clinical kidney journal·2021
Same author

Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

British journal of pharmacology·2021
Same author

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.

Circulation·2021
Same author

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.

Journal of the American Society of Nephrology : JASN·2021
Same author

Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Nature reviews. Nephrology·2021
Same author

Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm.

Hypertension (Dallas, Tex. : 1979)·2021

Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting.

Tamar S Polonsky1, George L Bakris2

  • 1Department of Medicine, Section of Cardiology, University of Chicago Medicine, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

Heart Failure Clinics
|September 2, 2019
PubMed
Summary

Heart failure impacts kidney function, increasing cardiovascular risk. Effective treatment combines renin-angiotensin system blockers, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors for reduced mortality.

Keywords:
CreatinineHeart failureHypertensionKidney

More Related Videos

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.9K

Related Experiment Videos

Last Updated: Jan 20, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.9K

Area of Science:

  • Cardiology
  • Nephrology
  • Cardiorenal Medicine

Background:

  • The kidney is a vital regulatory organ that adapts to cardiac function changes.
  • Bidirectional communication (cross-talk) exists between the heart and kidneys.
  • In heart failure, the kidney can be a bystander but also actively contributes to detrimental processes.

Purpose of the Study:

  • To discuss the pathophysiology of worsening kidney function in heart failure.
  • To explore the association between kidney function decline and patient prognosis.
  • To examine how impaired kidney function elevates cardiovascular risk.

Main Methods:

  • Review of existing literature on cardiorenal interactions in heart failure.
  • Analysis of the pathophysiological mechanisms linking kidney function and heart failure progression.
  • Synthesis of data regarding therapeutic strategies for patients with co-existing heart failure and kidney disease.

Main Results:

  • Worsening kidney function is linked to poorer prognosis in heart failure patients.
  • Kidney dysfunction contributes significantly to increased cardiovascular risk.
  • Specific drug classes are crucial for managing combined heart failure and kidney disease.

Conclusions:

  • Managing heart failure with co-existing kidney disease requires a multi-faceted pharmacological approach.
  • The combination of renin-angiotensin system blockers, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors is recommended.
  • This therapeutic strategy aims to reduce morbidity and mortality in this high-risk patient population.